Skip to main content

Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Correction

The authors [1] note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.

This is a Correction article on http://www.biomedcentral.com/1741-7015/11/43.

Table 1 Summary of laboratory parameters

References

  1. 1.

    Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine. 2013, 11: 43-10.1186/1741-7015-11-43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/11/193/prepub

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clifford J Bailey.

Additional information

The online version of the original article can be found at 10.1186/1741-7015-11-43

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Bailey, C.J., Gross, J.L., Hennicken, D. et al. Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11, 193 (2013). https://doi.org/10.1186/1741-7015-11-193

Download citation